The history of Sildenafil presents a complex case for stakeholders in the medicinal sector. While initially a phenomenal success, creating huge profits, the patent lapse and the subsequent flood of cheaper competitors have significantly impacted income. This raises questions about the long-term profitability of related therapeutic developments and